

## WEST Search History

[Hide Items](#) [Restore](#) [Clear](#) [Cancel](#)

DATE: Thursday, September 13, 2007

Hide?	<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L7	L5 not L6	58
<input type="checkbox"/>	L6	L5 and allergan\$.asn.	5
<input type="checkbox"/>	L5	L4 and (immune or antibodies or neutralizing or neutralise or neutralize or neutralising or igg or igm or iga or siga or immunoglobulin antiantibody or anti-igg or elisa or ria or eia or immunoassay).clm.	63
<input type="checkbox"/>	L4	L3 and (method or process).clm.	118
<input type="checkbox"/>	L3	peptide.clm. and botulin\$.clm.	135
<input type="checkbox"/>	L2	L1 and allergan\$.asn.	7
<input type="checkbox"/>	L1	Atassi.in.	186

END OF SEARCH HISTORY

1. 20070172497. 29 Mar 07. 26 Jul 07. BoNT/A PEPTIDES AND METHODS OF PREDICTING AND REDUCING IMMUNORESISTANCE TO BOTULINUM TOXIN THERAPY. Atassi; M. Zouhair. 424/239.1; A61K39/08 20060101

---

☐ 2. WO2006042149A2. 05 Oct 05. 20 Apr 06. DETERMINING AND REDUCING IMMUNORESISTANCE TO BOTULINUM TOXIN THERAPY USING BOTULINUM TOXIN A PEPTIDES. ATASSI, M ZOUHAIR. A61K039/08;

---

☐ 3. WO2006017715A2. 04 Aug 05. 16 Feb 06. BOTULINUM TOXIN TYPE A IMMUNORESISTANT ASSAY. ATASSI, ZOUHAIR M.

---

☐ 4. WO2005030119A2. 09 Apr 04. 07 Apr 05. BOTULINUM TOXIN A PEPTIDES AND METHODS OF PREDICTING AND REDUCING IMMUNORESISTANCE TO BOTULINUM TOXIN THERAPY. ATASSI, M ZOUHAIR. A61K00/;

---

☐ 5. WO2006042149A. Clostridium botulinum neurotoxin A peptide composition for determining immunoresistance to botulinum toxin therapy comprises specified epitopic sequences of heavy chain domains of the peptide. ATASSI, M Z. C07K000/00.

---

☐ 6. WO2006017715A. Determining Botulinum Toxin Type A (BoNT/A) immunoresistance in a mammal, by adding a BoNT/A toxin and a BoNT/A receptor to a test sample, and detecting the amount of toxin-receptor complexes formed in the test sample. ATASSI, Z M. G01N033/569.

---

☐ 7. US20040265935A. Predicting or determining immunoresistance to botulinum toxin therapy in individuals, by determining presence/absence in individual of antibodies immunoreactive with botulinum neurotoxin A peptide. ATASSI, M Z. A61K000/00 G01N033/554 G01N033/569.